Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hepatitis C virus inhibitors - Progenics

Next Previous
Drug Profile

Research programme: hepatitis C virus inhibitors - Progenics

Alternative Names: PRO 206

Latest Information Update: 23 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Progenics Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Mar 2012 Discontinued for Hepatitis C in USA (PO)
  • 23 Nov 2011 Research programme: hepatitis C virus inhibitors - Progenics is available for licensing as of 09 Nov 2011. http://www.progenics.com
  • 18 Apr 2010 Pharmacodynamics data from a preclinical trial in Hepatitis C presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top